公开(公告)号：US20190169621A1

公开(公告)日：2019-06-06

申请号：US16263157

申请日：2019-01-31

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  SREESHA P. SRINIVASA ,  USHA BUGHANI ,  RESHMI NAIR

IPC: C12N15/62 ,  C12N5/00 ,  G01N33/68 ,  C07K16/32 ,  C07K16/28 ,  C07K14/705 ,  C07K14/65 ,  C07K14/495 ,  C07K14/71 ,  C07K7/08 ,  C07K14/00 ,  A61K48/00 ,  A61K39/395 ,  C07K16/30 ,  A61K38/10 ,  A61K38/17 ,  A61K45/06

Abstract: The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

公开(公告)号：US20160237155A1

公开(公告)日：2016-08-18

申请号：US15145135

申请日：2016-05-03

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  KEDARNATH SASTRY ,  MARIA MELINA SOARES

IPC: C07K16/28 ,  C07K14/71

CPC classification number: C12N15/62 ,  A61K38/00 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2121/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N5/0018 ,  C12N2500/22 ,  G01N33/6854

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

公开(公告)号：US20160168260A1

公开(公告)日：2016-06-16

申请号：US15047062

申请日：2016-02-18

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  KEDARNATH SASTRY ,  MARIA MELINA SOARES

IPC: C07K16/30 ,  C07K7/08 ,  A61K38/10 ,  A61K39/395 ,  A61K38/17 ,  C07K14/71 ,  A61K45/06

CPC classification number: C12N15/62 ,  A61K38/00 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2121/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N5/0018 ,  C12N2500/22 ,  G01N33/6854

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

公开(公告)号：US20210301296A1

公开(公告)日：2021-09-30

申请号：US17339112

申请日：2021-06-04

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  KEDARNATH SASTRY ,  MARIA MELINA SOARES

IPC: C12N15/62 ,  C07K14/495 ,  C07K14/65 ,  C07K14/705 ,  C07K16/28 ,  C07K16/32 ,  C07K14/00 ,  G01N33/68 ,  A61K38/10 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K7/08 ,  C07K14/71 ,  C07K16/30 ,  A61K48/00 ,  C12N5/00

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

公开(公告)号：US20170233747A1

公开(公告)日：2017-08-17

申请号：US15444527

申请日：2017-02-28

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  KEDARNATH SASTRY ,  MARIA MELINA SOARES

IPC: C12N15/62 ,  A61K39/395 ,  A61K48/00 ,  C12N5/00

CPC classification number: C12N15/62 ,  A61K38/00 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2121/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N5/0018 ,  C12N2500/22 ,  G01N33/6854

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

公开(公告)号：US20140356362A1

公开(公告)日：2014-12-04

申请号：US14458674

申请日：2014-08-13

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  KEDARNATH SASTRY ,  MARIA MELINA SOARES

IPC: C07K16/28 ,  G01N33/68 ,  C07K14/00

CPC classification number: C12N15/62 ,  A61K38/00 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2121/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N5/0018 ,  C12N2500/22 ,  G01N33/6854

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

Abstract translation: 本发明一般涉及产生用于癌症治疗的融合蛋白的领域，更具体地，涉及编码融合蛋白的核苷酸序列，其中所述嵌合融合蛋白包含至少一个靶向部分和至少一个抵抗的免疫调节部分 癌细胞的免疫耐受。

公开(公告)号：US20130287802A1

公开(公告)日：2013-10-31

申请号：US13799409

申请日：2013-03-13

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  Kedarnath Sastry ,  Maria Melina Soares

IPC: C07K16/28

CPC classification number: C12N15/62 ,  A61K38/00 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2121/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N5/0018 ,  C12N2500/22 ,  G01N33/6854

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

Abstract translation: 本发明一般涉及产生用于癌症治疗的融合蛋白的领域，更具体地，涉及编码融合蛋白的核苷酸序列，其中所述嵌合融合蛋白包含至少一个靶向部分和至少一个抵抗的免疫调节部分 癌细胞的免疫耐受。